Agios Pharmaceuticals, Inc. (AGIO) Given a $90.00 Price Target at Canaccord Genuity
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) received a $90.00 target price from stock analysts at Canaccord Genuity in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price target indicates a potential upside of 51.24% from the company’s current price.
Other research analysts have also issued research reports about the company. SunTrust Banks, Inc. reissued a “buy” rating and set a $80.00 price objective (up previously from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday. Cann reaffirmed a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Leerink Swann raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Janney Montgomery Scott reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, August 1st. Finally, BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $68.67.
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.54% on Tuesday, hitting $59.51. 1,058,869 shares of the stock were exchanged. The firm’s market cap is $2.87 billion. The company has a 50-day moving average price of $56.10 and a 200-day moving average price of $51.23. Agios Pharmaceuticals has a 52-week low of $35.84 and a 52-week high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by $0.21. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The business had revenue of $11.30 million for the quarter, compared to analysts’ expectations of $10.68 million. During the same period in the previous year, the firm posted ($1.47) EPS. The firm’s revenue for the quarter was up 62.1% compared to the same quarter last year. On average, equities research analysts anticipate that Agios Pharmaceuticals will post ($6.43) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/agios-pharmaceuticals-inc-agio-given-a-90-00-price-target-at-canaccord-genuity.html.
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $50.87, for a total value of $101,740.00. Following the completion of the sale, the director now owns 90,197 shares in the company, valued at $4,588,321.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $50.02, for a total value of $150,060.00. Following the completion of the sale, the chief executive officer now owns 1,100 shares of the company’s stock, valued at approximately $55,022. The disclosure for this sale can be found here. Insiders sold 79,120 shares of company stock valued at $4,557,207 in the last quarter. Corporate insiders own 10.55% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. FMR LLC increased its position in shares of Agios Pharmaceuticals by 0.5% in the first quarter. FMR LLC now owns 6,331,747 shares of the biopharmaceutical company’s stock worth $369,774,000 after buying an additional 32,931 shares in the last quarter. BB Biotech AG increased its position in shares of Agios Pharmaceuticals by 1.1% in the first quarter. BB Biotech AG now owns 2,839,528 shares of the biopharmaceutical company’s stock worth $165,828,000 after buying an additional 30,000 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Agios Pharmaceuticals by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,597,391 shares of the biopharmaceutical company’s stock worth $151,688,000 after buying an additional 129,159 shares in the last quarter. BlackRock Inc. increased its position in shares of Agios Pharmaceuticals by 8,463.5% in the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after buying an additional 2,141,768 shares in the last quarter. Finally, First Trust Advisors LP increased its position in shares of Agios Pharmaceuticals by 52.3% in the second quarter. First Trust Advisors LP now owns 973,870 shares of the biopharmaceutical company’s stock worth $50,106,000 after buying an additional 334,291 shares in the last quarter. Hedge funds and other institutional investors own 84.53% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.